{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:33:12Z","timestamp":1774567992919,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Biotechnology, Government of India","award":["BT\/PR15750\/MED\/29\/1015\/2016"],"award-info":[{"award-number":["BT\/PR15750\/MED\/29\/1015\/2016"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>The emergence of drug resistance and cross-resistance to existing drugs has warranted the development of new antivirals for Herpes simplex viruses (HSV). Hence, we have designed this study to evaluate the anti-viral activity of 1-[(2-methyl benzimidazole-1-yl) methyl]-2-oxo-indolin-3-ylidene] amino] thiourea (MBZM-N-IBT), against HSV-1.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>Molecular docking was performed to assess the affinity of MBZM-N-IBT for HSV-1 targets. This was validated by plaque assay, estimation of RNA and protein levels as well as time of addition experiments in vitro.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>Molecular docking analysis suggested the inhibitory capacity of MBZM-N-IBT against HSV-1. This was supported by the abrogation of the HSV-1 infectious viral particle formation with the IC<jats:sub>50<\/jats:sub>value of 3.619\u00a0\u00b5M. Viral mRNA levels were also reduced by 72% and 84% for UL9 and gC respectively. MBZM-N-IBT also reduced the protein synthesis for gC and ICP8 significantly. While mRNA of ICP8 was not significantly affected, its protein synthesis was reduced by 47%. The time of addition experiment revealed the capacity of MBZM-N-IBT to inhibit HSV-1 at early as well as late stages of infection in the Vero cells. Similar effect of MBZM-N-IBT was also noticed in the Raw 264.7 and BHK 21 cells after HSV-1 infection. Supported by the in silico data, this can be attributed to possible interference with multiple HSV targets including the ICP8, ICP27, UL42, UL25, UL15 and gB proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results along with the lack of acute oral toxicity and significant anti-inflammatory effects suggest its suitability for further evaluation as a non-nucleoside inhibitor of HSV.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-021-01581-5","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T20:03:20Z","timestamp":1622059400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Inhibition of herpes simplex virus-1 infection by MBZM-N-IBT: in silico and in vitro studies"],"prefix":"10.1186","volume":"18","author":[{"given":"Abhishek","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saikat","family":"De","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok Kumar","family":"Moharana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tapas Kumar","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Saswat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ankita","family":"Datey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhudutta","family":"Mamidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadarsee","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bharat Bhusan","family":"Subudhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8378-1014","authenticated-orcid":false,"given":"Soma","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"1581_CR1","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/S0140-6736(00)04638-9","volume":"357","author":"J Richard","year":"2001","unstructured":"Richard J, Whitley B. Herpes simplex virus infections. Lancet. 2001;357:1513\u20138.","journal-title":"Lancet"},{"key":"1581_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.antiviral.2003.09.006","volume":"61","author":"RC Brady","year":"2004","unstructured":"Brady RC, Bernstein DI. Treatment of herpes simplex virus infections. Antiviral Res. 2004;61:73\u201381.","journal-title":"Antiviral Res"},{"key":"1581_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/spid.2003.127224","volume":"14","author":"DW Kimberlin","year":"2003","unstructured":"Kimberlin DW. Herpes simplex virus infections of the central nervous system. Semin Pediatr Infect Dis. 2003;14:83\u20139.","journal-title":"Semin Pediatr Infect Dis"},{"key":"1581_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.antiviral.2003.09.006","volume":"61","author":"I Bernstein","year":"2004","unstructured":"Bernstein I. RCB: Treatment of herpes simplex virus infections. Antiviral Res. 2004;61:73\u201381.","journal-title":"Antiviral Res"},{"key":"1581_CR5","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1073\/pnas.77.4.2265","volume":"77","author":"DM Coen","year":"1980","unstructured":"Coen DM, Schaffer PA. Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1. Proc Natl Acad Sci U S A. 1980;77:2265\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1581_CR6","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1128\/AAC.00615-10","volume":"55","author":"JPAG Boivin","year":"2011","unstructured":"Boivin JPAG. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemotherapy. 2011;55:459\u201372.","journal-title":"Antimicrob Agents Chemotherapy"},{"key":"1581_CR7","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1167\/iovs.08-2077","volume":"49","author":"PS Bhattacharjee","year":"2008","unstructured":"Bhattacharjee PS, Neumann DM, Foster TP, Clement C, Singh G, Thompson HW, Kaufman HE, Hill JM. Effective treatment of ocular HSK with a human apolipoprotein E mimetic peptide in a mouse eye model. Invest Ophthalmol Vis Sci. 2008;49:4263\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1581_CR8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/135965350701200608","volume":"12","author":"P Bonnafous","year":"2007","unstructured":"Bonnafous P, Naesens L, Petrella S, Gautheret-Dejean A, Boutolleau D, Sougakoff W, Agut H. Different mutations in the HHV-6 DNA polymerase gene accounting for resistance to foscarnet. Antivir Ther. 2007;12:877\u201388.","journal-title":"Antivir Ther"},{"key":"1581_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/infdis\/169.1.193","volume":"169","author":"S Safrin","year":"1994","unstructured":"Safrin S, Kemmerly S, Plotkin B, Smith T, Weissbach N, De Veranez D, Phan LD, Cohn D. Foscarnet-resistant herpes simplex virus infection in patients with AIDS. J Infect Dis. 1994;169:193\u20136.","journal-title":"J Infect Dis"},{"key":"1581_CR10","doi-asserted-by":"crossref","unstructured":"Martin EHAAR: Studies in the chemotherapy of tuberculosis: part vii. the oxidation and reduction products of thiosemicarbazones. Brit J Pharmacol. 1951; 454.","DOI":"10.1111\/j.1476-5381.1951.tb00656.x"},{"key":"1581_CR11","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.bmcl.2011.02.037","volume":"21","author":"IJ Kang","year":"2011","unstructured":"Kang IJ, Wang LW, Hsu TA, Yueh A, Lee CC, Lee YC, Lee CY, Chao YS, Shih SR, Chern JH. Isatin-beta-thiosemicarbazones as potent herpes simplex virus inhibitors. Bioorg Med Chem Lett. 2011;21:1948\u201352.","journal-title":"Bioorg Med Chem Lett"},{"key":"1581_CR12","doi-asserted-by":"publisher","first-page":"8694","DOI":"10.1016\/S0021-9258(17)39404-8","volume":"260","author":"T Spector","year":"1985","unstructured":"Spector T, Joens TE. Herpes simplex type1 ribonucleotide reductase. J Biol Chem. 1985;260:8694\u20137.","journal-title":"J Biol Chem"},{"key":"1581_CR13","doi-asserted-by":"publisher","first-page":"20122","DOI":"10.1038\/srep20122","volume":"6","author":"P Mishra","year":"2016","unstructured":"Mishra P, Kumar A, Mamidi P, Kumar S, Basantray I, Saswat T, Das I, Nayak TK, Chattopadhyay S, Subudhi BB, Chattopadhyay S. Inhibition of Chikungunya Virus Replication by 1-[(2-Methylbenzimidazol-1-yl) Methyl]-2-Oxo-Indolin-3-ylidene] Amino] Thiourea(MBZM-N-IBT). Sci Rep. 2016;6:20122.","journal-title":"Sci Rep"},{"key":"1581_CR14","first-page":"119","volume":"24","author":"H Jankowska","year":"1970","unstructured":"Jankowska H. Attempt at treatment with methisazone of an infant with vaccinia and herpes simplex viruses. Przegl Epidemiol. 1970;24:119\u201321.","journal-title":"Przegl Epidemiol"},{"key":"1581_CR15","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1128\/JVI.75.5.2353-2367.2001","volume":"75","author":"J Burkham","year":"2001","unstructured":"Burkham J, Coen DM, Hwang CB, Weller SK. Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments. J Virol. 2001;75:2353\u201367.","journal-title":"J Virol"},{"key":"1581_CR16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455\u201361.","journal-title":"J Comput Chem"},{"key":"1581_CR17","doi-asserted-by":"publisher","first-page":"13659","DOI":"10.1128\/JVI.01204-07","volume":"81","author":"S Chattopadhyay","year":"2007","unstructured":"Chattopadhyay S, Weller SK. Direct interaction between the N- and C-terminal portions of the herpes simplex virus type 1 origin binding protein UL9 implies the formation of a head-to-tail dimer. J Virol. 2007;81:13659\u201367.","journal-title":"J Virol"},{"key":"1581_CR18","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00705-015-2564-2","volume":"160","author":"S Kumar","year":"2015","unstructured":"Kumar S, Mamidi P, Kumar A, Basantray I, Bramha U, Dixit A, Maiti PK, Singh S, Suryawanshi AR, Chattopadhyay S, Chattopadhyay S. Development of novel antibodies against non-structural proteins nsP1, nsP3 and nsP4 of chikungunya virus: potential use in basic research. Arch Virol. 2015;160:2749\u201361.","journal-title":"Arch Virol"},{"key":"1581_CR19","doi-asserted-by":"crossref","unstructured":"Nayak TK, Mamidi P, Kumar A, Singh LP, Sahoo SS, Chattopadhyay S, Chattopadhyay S: Regulation of viral replication, apoptosis and pro-inflammatory responses by 17-AAG during chikungunya virus infection in macrophages. Viruses 2017, 9.","DOI":"10.3390\/v9010003"},{"key":"1581_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1128\/AAC.29.2.278","volume":"29","author":"WG Liu","year":"1986","unstructured":"Liu WG, Chen ZJ, Song JZ, Ma ZX. Effects of 2,2\u2019-O-cyclocytidine and acyclovir on latent herpes simplex virus in trigeminal ganglia of mice. Antimicrob Agents Chemother. 1986;29:278\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"1581_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/prot.10286","volume":"50","author":"SC Lovell","year":"2003","unstructured":"Lovell SC, Davis IW, Arendall WB 3rd, de Bakker PI, Word JM, Prisant MG, Richardson JS, Richardson DC. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins. 2003;50:437\u201350.","journal-title":"Proteins"},{"key":"1581_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1471-2105-2-5","volume":"2","author":"S Cristobal","year":"2001","unstructured":"Cristobal S, Zemla A, Fischer D, Rychlewski L, Elofsson A. A study of quality measures for protein threading models. BMC Bioinformatics. 2001;2:5.","journal-title":"BMC Bioinformatics"},{"key":"1581_CR23","doi-asserted-by":"publisher","first-page":"9803","DOI":"10.1073\/pnas.1733876100","volume":"100","author":"CY Eom","year":"2003","unstructured":"Eom CY, Lehman IR. Replication-initiator protein (UL9) of the herpes simplex virus 1 binds NFB42 and is degraded via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A. 2003;100:9803\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1581_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1128\/JVI.67.2.711-715.1993","volume":"67","author":"PE Boehmer","year":"1993","unstructured":"Boehmer PE, Lehman IR. Herpes simplex virus type 1 ICP8: helix-destabilizing properties. J Virol. 1993;67:711\u20135.","journal-title":"J Virol"},{"key":"1581_CR25","doi-asserted-by":"publisher","first-page":"8828","DOI":"10.1128\/JVI.00441-15","volume":"89","author":"V Patel","year":"2015","unstructured":"Patel V, Dahlroth SL, Rajakannan V, Ho HT, Cornvik T, Nordlund P. Structure of the C-terminal domain of the multifunctional ICP27 protein from herpes simplex virus 1. J Virol. 2015;89:8828\u201339.","journal-title":"J Virol"},{"key":"1581_CR26","doi-asserted-by":"crossref","unstructured":"Ekaterina E. Heldwein HL, Florent C. Bender, Gary H. Cohen, Roselyn J. Eisenberg, Stephen C. Harrison: Crystal structure of glycoprotein B from herpes simplex virus 1. 2006, 313:217\u2013220.","DOI":"10.1126\/science.1126548"},{"key":"1581_CR27","doi-asserted-by":"crossref","unstructured":"Brian R. Bowman, Robert L. Welschhans, Hariharan Jayaram,\u2021, Nigel D. Stow, Valerie G. Preston, and Florante A. Quiocho: Structural characterization of the UL25 DNA-packaging protein from herpes simplex virus Type 1. Journal of Virology 2006, 80:2309\u20132317.","DOI":"10.1128\/JVI.80.5.2309-2317.2006"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-021-01581-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-021-01581-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,4]],"date-time":"2023-11-04T05:48:36Z","timestamp":1699076916000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-021-01581-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1581"],"URL":"https:\/\/doi.org\/10.1186\/s12985-021-01581-5","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]},"assertion":[{"value":"28 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare that they have no competing of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}